Clinical Trials · NCT02058147

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Name: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lixisenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 1,170
Start date: Feb 2014
Locations: 273 sites, 23 countries
Primary endpoint: Change in HbA1c From Baseline to Week 30

View Lixisenatide compound reference